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Successfully reprogramming somatic cells to a pluripotent state generates induced pluripotent stem (iPS) cells (or
iPSCs), which have extensive self-renewal capacity like embryonic stem cells (ESCs). iPSCs can also generate daughter
cells that can further undergo differentiation into various lineages or terminally differentiate to reach their final
functional state. The discovery of how to produce iPSCs opened a new field of stem cell research with both intellectual
and therapeutic benefits. The huge potential implications of disease-specific or patient-specific iPSCs have impelled
scientists to solve problems hindering their applications in clinical medicine, especially the issues of convenience and
safety. To determine the range of tissue types amenable to reprogramming as well as their particular characteristics,
cells from three embryonic germ layers have been assessed, and the advantages that some tissue origins have over
fibroblast origins concerning efficiency and accessibility have been elucidated. To provide safe iPSCs in an efficient and
convenient way, the delivery systems and combinations of inducing factors as well as the chemicals used to generate
iPSCs have also been significantly improved in addition to the efforts on finding better donor cells. Currently, iPSCs can
be generated without c-Myc and Klf4 oncogenes, and non-viral delivery integration-free chemically mediated
reprogramming methods have been successfully employed with relatively satisfactory efficiency. This paper will review
recent advances in iPS technology by highlighting tissue origin and generation of iPSCs. The obstacles that need to be
overcome for clinical applications of iPSCs are also discussed.
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Induced pluripotent stem (iPS) cells (or iPSCs) have an
extensive capacity for self-renewal, reproduction and dif-
ferentiation, much like embryonic stem cells (ESCs).
Disease-specific or patient-specific iPSCs have both in-
tellectual (e.g., disease modeling) and therapeutic bene-
fits, and yet iPSCs face certain obstacles that hinder
their applications in clinical medicine, especially the is-
sues of convenience and safety.
Cells from three embryonic germ layers have been
assessed to determine the range of tissue types amenable
to reprogramming along with their particular characteris-
tics. Some tissue origins have advantages over fibroblast* Correspondence: SDSLYYSW@163.com
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unless otherwise stated.origins with respect to efficiency and accessibility. Human
urine-derived cells can be an attractive choice from which
to generate iPSCs.
The delivery systems and combinations of inducing
factors as well as the chemicals used to generate iPSCs
have also been significantly improved to provide safe
iPSCs in an efficient and convenient way. Small mol-
ecule strategy is much more promising because of its
many advantages.
Extensive genetic screening and in vivo immunogen-
icity testing should be standard procedure to ensure the
safety of human iPSCs prior to their clinical use.Introduction
Embryonic stem cells (ESCs), which are derived from
the inner cell mass of mammalian blastocyst, have the
ability to grow indefinitely while maintaining pluripo-
tency and the ability to differentiate into cells of all threehis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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play important roles in the maintenance of ESC identity
also play pivotal roles in the induction of pluripotency in
somatic cells, in 2006, Takahashi et al. selected 24 candi-
date genes for inducing pluripotency in somatic cells
under ESC culture conditions [1]. They successfully con-
verted mouse embryonic fibroblasts (MEFs) and adult
tail-tip fibroblasts (TTFs) to an undifferentiated state
similar to that of ESCs through retroviral transduction
of four transcription factors: Oct 3/4 (O), Sox2 (S), Klf4
(K), and c-Myc (M). These cells were termed induced
pluripotent stem (iPS) cells (iPSCs). Subsequently, they
generated human iPSCs (hiPSCs) from human dermal fi-
broblasts (HDFs) in the same way [2]. These hiPSCs
were also generated by Yu et al. from fetal fibroblasts,
newborn foreskin fibroblasts (BJ fibroblasts), and primary
human fibroblast-like synoviocytes (HFLS) by introducing
another four factors, namely, Oct3/4, Sox2, Nanog (N),
and Lin28 (L), using lentiviral vectors [3].
Although the reprogramming process has been grad-
ually revealed by intensive studies, the role of these tran-
scription factors and the way they function in the
acquisition and maintenance of pluripotency are still not
fully understood. Simply speaking, the identity of som-
atic cells is strictly protected by an epigenetic barrier,
and these cells acquire pluripotency when the reprogram-
ming factors break the epigenetic barrier [4]. Possible
mechanisms include silencing of retroviral transgenes
upon establishment of pluripotency [5], reactivation of en-
dogenous pluripotency genes [1], establishment of bivalent
chromatin domains in the promoters of developmentally
regulated genes [6], global DNA hypomethylation and
DNA hypermethylation of imprinted gene loci [7], reacti-
vation of the inactive X chromosome in female iPSCs and
reorganization of chromatin fibers [8].
iPSCs are found to be similar to ES in their morph-
ology, proliferation, surface antigens, gene expression,
epigenetic status of their pluripotent cell-specific genes,
and telomerase activity. Furthermore, these cells can dif-
ferentiate into cell types of the three germ layers in vitro
as well as into teratomas in vivo. They are also capable
of germline transmission [9]. Nevertheless, iPSCs are su-
perior to ESCs in some aspects because they have the
potential to bypass both the practical and ethical con-
cerns associated with ESCs. Unlike ESCs, which require
the use of embryos and are thus complicated by ethical
controversies and possible immune rejection, iPSCs can
be derived from directed reprogramming of somatic cells
from individual patients. Because the lifespan of fully dif-
ferentiated cells is usually short and because such cells
cannot self-renew (with a few exceptions, e.g., hepato-
cytes), iPS technology can provide them with an exten-
sive ESC-like capacity to self-renew and the ability to
generate daughter cells that can further differentiate intovarious lineages or terminally differentiate into a func-
tional state, thus opening a new field of stem cell re-
search. These disease-specific or patient-specific stem
cells provide a unique opportunity to understand novel
disease mechanisms [10], to screen for more effective
and safe drugs [11], to develop autologous cell therapies
including in vitro expansion and differentiation into cells
of the hematopoietic lineage [12,13], and to treat various
diseases and injuries, such as Parkinson's disease [14]
and cardiac damage [15].
Despite the potential implications of this technology, a
number of questions about iPSC generation must be an-
swered. There are several potential challenges to their pos-
sible clinical application in humans: (i) virus-mediated
delivery of reprogramming factors permanently integrates
transgenes into the human genome, potentially altering
genomic features and risking viral transgene reactivation
[16]; (ii) the reprogramming factors Klf4 and c-Myc are
oncogenic and can potentially lead to the development of
certain cancers [17,18]; (iii) the low efficiency of iPS in-
duction [1] and the lack of full and homogeneous iPS re-
programming processes are both problematic.
A series of major breakthroughs have been achieved.
To determine the range of tissue types amenable to re-
programming, to decrease the tumorigenesis risk from
transgene integration, and to increase the induction effi-
ciency, investigators have extensively studied cells from
three embryonic germ layers and identified some advan-
tages of using tissues other than fibroblast. Delivery sys-
tems and combinations of inducing factors, as well as
the chemicals used to generate iPSCs have also been im-
proved; for example, iPSCs can now be generated without
the use of the oncogenes c-Myc and Klf4 [19], and non-
viral integration-free delivery methods are being success-
fully employed with reasonable efficiency. In this paper,
we review recent advances in iPS technology, with a par-
ticular focus on tissue origin and generation of iPSCs.
Tissue origins of iPSCs
Fibroblasts are the first cell type to have been success-
fully reprogrammed into iPSCs. Takahashi et al. tried 24
candidate genes and found that the retroviral transduc-
tion of OSKM reprogrammed MEFs and somatic TTFs
into iPSCs [1]. These cells were also used to generate
hiPSCs [2]. Fibroblasts are still widely used in iPSC tech-
nology, and their reprogramming efficiency and differenti-
ation ability are the gold standard to which new methods
must be compared.
Studying the strategy of iPSC production is different in
different species due to practical and ethical concerns.
iPSCs have been generated from mouse, rat [20], monkey
[21], pig [22], dog [23], rabbit [24], and human cells. Pluri-
potency has been exhaustively analyzed in mice: iPSCs
can form teratomas, which are differentiated tumors with
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tribute to all tissue types, including the germ line, when
injected into murine blastocysts. iPSCs from MEFs could
generate “all-iPSC mice” following injection into tetra-
ploid blastocysts, thereby satisfying the most stringent
criterion of pluripotency [1]. The same procedures can-
not be applied to hiPSCs, which must rely on embryonic
bodies and teratomas as the most stringent tests. This
paper will only focus on iPSCs of mouse and human
origin.
Cells from the three embryonic germ layers have been
studied by researchers in the iPS field to determine the
range of tissue types amenable to reprogramming, to de-
crease the tumorigenesis risk of transgene integration,
and to increase the efficiency of induction. Malignant
cell lines and primary cancer cells are also confirmed to
be amenable to reprogramming by the iPS approach;
however, this issue is not reviewed in this paper. To bet-
ter understand the differences that result from the tissue
origin of iPSCs, we will discuss them through two per-
spectives: differences within the same tissue origin and
differences resulting from different tissue origins.
Differences within the same tissue origin
Efficiency
The efficiency of iPSC induction is defined as the per-
centage of green fluorescent protein (GFP)-positive col-
onies with clear iPS morphology with a certain amount
of mother cells transfected with transgenes. The efficien-
cies of iPSC induction from a single tissue of origin are
different when using different technologies. It is hard to
accurately correctly compare induction efficiency of dif-
ferent methods given differences in their experimental
settings. Furthermore, efficiency is indeed an important
criterion for an induction technology, but it is not always
the most important one. Some technologies were im-
proved to reduce integration of transgenes while sacri-
ficing efficiency. In general, there are a few lessons
regarding the efficiencies of iPSC induction from a single
tissue origin: (i) efficiency is higher in mice than in hu-
man, successful induction using some technologies has
not been reported in humans due to very low efficiency;
(ii) decreasing the number of transgenes with the same
methods would reduce the induction efficiency by orders
of magnitude; (iii) non-integration methods are much
less efficient than integration methods, with the excep-
tion of the Sendai virus (SeV) versus retrovirus and
lentivirus vectors; (iv) certain chemicals and microRNAs
(miRNAs) can also markedly improve the efficiency. A
detailed summary of the efficiencies of different induc-
tion methods using fetal and somatic fibroblasts are
listed chronologically in Table 1 according to the publi-
cation date of descriptive papers, which straightfor-
wardly represents the development of the technology.Another example of different efficiencies in the same
tissue origin in response to different induction technolo-
gies is found in human adipose stem cells (hASCs). Sun
et al. [42] reported that when hASCs are transduced
with individual lentiviruses containing OSKM, the inci-
dence of ESC-like colonies is 0.2%, whereas Vc or Vc +
VPA with retroviral pMX vectors containing OSKM
cDNAs reprogrammed hASCs with a much higher effi-
ciency (up to 7.06%) [32], nevertheless, the reprogram-
ming efficiency is much lower with minicircle DNA,
which contains a single cassette of OSNL plus a GFP re-
porter gene separated by self-cleavage peptide 2A se-
quences. This system yields an overall reprogramming
efficiency of ~0.005% [39].
Some small molecules can increase the efficiency of re-
programming primary human fibroblasts to a pluripo-
tent state [26]. When the same three-factor combination
(OSK) via retroviral transduction is used, the addition
of VPA improves reprogramming efficiency by a factor
of 1,000-fold. Furthermore, VPA could enable repro-
gramming with only two factors (Oct4 and Sox2) with
efficiency similar to that of three factors, suggesting that
VPA treatment effectively dispenses the need for Klf4.
Other small molecules that could obviate the need for
certain exogenous factors will be reviewed below.
Somatic coding mutations
Somatic coding mutations of iPSCs are different even
with the same cell origin. The majority of protein-
coding exons (exomes) in the 22 hiPS cell lines repro-
grammed using five different methods were sequenced.
Three of these lines had been produced via integrating
methods (four-factor retroviral, four-factor lentiviral and
three-factor retroviral) and two non-integrating methods
(EV and messenger RNA (mRNA) delivery into the fi-
broblasts) in seven laboratories and from nine matched
fibroblast lines [43]. It was found that these cell lines
contained an average of five protein-coding point muta-
tions in the regions sampled (with an estimated six
protein-coding point mutations per exome). The major-
ities of these mutations are non-synonymous, nonsense,
or splice variants and are enriched in genes that have
been associated with cancers. At least half of these
reprogramming-associated mutations are found to pre-
exist in fibroblast progenitors at low frequency, while
the rest occur during or after reprogramming. It should
be considered whether some of these mutations could
increase the risk of disease when hiPS-cell-derived cells/
tissues are used in the clinic. Although the functional ef-
fects of the mutations remain to be characterized experi-
mentally, it is nonetheless striking that the observed
reprogramming-associated mutational load shares many
similarities with characteristics observed in cancer. Fur-
thermore, the observation of mutated genes involved in
Table 1 Efficiency of different iPS induction methods in fibroblasts
Delivery system Species Technology Efficiency (%) reference
Virus M OSKM/retrovirus 0.001 ~ 0.01 [1]
H OSKM/retrovirus 0.02 [2]
H OSNL/lentivirus 0.01 ~ 0.02 [3]
M, H OSK/retrovirus <0.001 [25]
M OSK/retrovirus + VPA 2 [26]
H OSK/retrovirus + VPA 1 [19]
OS/retrovirus + VPA <0.001
M OSKM/adenovirus 0.0001 ~ 0.001 [27]
H OSKM/retrovirus/p53 siRNA and UTF1 2 [28]
M OSKM/a single polycistronic retrovirus 0.0001 [29]
M OSKM/retrovirus/p53 siRNA 20 [30]
OSK/retrovirus/p53 siRNA 10
H OSKM/SeV ~1% [31]
M pMX-OSKM cDNA/retrovirus + Vc 8.75 [32]
H OSKM/retrovirus + VPA + Vc 6.2 [33]
Plasmids M pCX-cMyc + pCX-OSK-2A 0.0001 ~ 0.0003 [34]
EV H IRES2 -mediated OSNLKM + SV40LT 0.0003-0.0006 [35]
Protein M OSKM + VPA/recombinant protein 0.006 [36]
OSK + VPA/recombinant protein 0.001
H OSKM/cell extract 0.001 [37]
Modified-RNA H OSKML 2(KSOML), 1.4(KSOM) [38]
Minicircle DNA H OSNL ~0.0005 [39]
Artificial chromosome vectors H OSKM 0.001%. [40]
Small-molecule compounds M 7 small-molecule compounds 0.2 [41]
Abbreviations: M mouse, H human, oriP/EBNA1 Epstein-Barr nuclear antigen-1, EV episomal vectors, IRES2 internal ribosome entry site 2, SV40LT SV40 large T gene,
VPA valproic acid, Vc vitamin C, siRNA small-interfering RNA.
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eases other than cancer should be evaluated as well for
hiPS-cell-based therapeutic methods. Thus, although all
hiPSC lines are extensively characterized for pluripo-
tency and have normal karyotypes before DNA extrac-
tion, pre-existing and new mutations occur during and
after reprogramming. These mutations can produce gen-
etic and epigenetic changes in the hiPSCs such that ex-
tensive genetic screening should become a standard
procedure to ensure the safety of hiPSCs before clinical
use. One corollary is that if reprogramming efficiency is
improved to a level such that no colony picking and
clonal expansion is necessary, the resultant hiPSCs could
potentially be free of mutations.
Copy number variations (CNVs)
Significantly more CNVs are present in early-passage
hiPSCs than in intermediate passage hiPSCs established
either by retroviral or piggyBac (PB) transposon delivery
methods [44]. Fortunately, most CNVs render the af-
fected cells at a selective disadvantage; thus remarkably,the expansion of hiPSCs in culture selects rapidly against
mutated cells, driving the lines toward a genetic state re-
sembling human ESCs.
Differences resulting from different tissue origins
Accessibility and universality
There is still no consensus regarding the preferred tissue
from which to harvest donor cells for iPSC reprogram-
ming. The ideal cell source should be easily accessible,
susceptible, and universal (any age, sex, ethnic group,
and body condition). Different cell sources are associated
with distinct advantages and disadvantages.
Dermal fibroblasts are currently the most frequently
used cells for reprogramming, but their obtainment re-
quires biopsy, and candidates sometimes refuse to do-
nate the necessary tissue. Additionally, the procedure is
contraindicated in life-threatening skin diseases (e.g., se-
vere epidermolysis bullosa) or burn cases. Keratinocytes
have similar limitations [45]. They are keratin-dense epi-
thelial cells and generate the outer protective epidermal
barrier of the skin surface as well as appendages such as
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multipotent progenitor cells similar to the ones from
fibroblast and the keratinocytic lineage can be readily
and safely derived from adipose tissue of adult humans
in very large quantities by lipoaspiration without ex-
tended time for expansion, but lipoaspiration is invasive
and sometimes harmful.
It is unclear if dermal papilla (DP) cells [46], which are
specialized skin fibroblasts that are considered to in-
struct hair follicle stem cells, are a good source for re-
programming because the growth and quality of hair
follicles depend on age, genotype, and medical condi-
tions of the human donors, although they are repro-
grammed more efficiently than skin and embryonic
fibroblasts due to high endogenous expression of Sox2
and c-Myc.
Blood cells are among the most favorable cell types for
iPSC induction, but their development has thus far been
disappointing. They include stem/progenitor cells and
terminal blood cells. Hematopoietic stem/progenitor
cells are young cells that are expected to carry minimal
somatic mutations and possess the immunological im-
maturity of newborn cells. They are rare in peripheral
blood but are naturally rich in the bone marrow (BM),
umbilical cord blood (CB), and placenta. Harvesting mo-
bilized CD34+ cells isolated from peripheral blood is a
cumbersome, expensive, and time-consuming process
[47] and granulocyte colony stimulating factor (G-CSF)
mobilization is a procedure that is frequently associated
with significant side effects, including bone pain, head-
ache, fatigue, and nausea [48]. BM harvesting is an inva-
sive procedure [49]. Other choices are the CB and the
placenta [50], which are extra-embryonic tissues of par-
ticular interest in regenerative medicine. They share an
early developmental origin and are a source of vast
amounts of cells with multilineage differentiation poten-
tial. They are also poorly immunogenic and, unlike many
other stem-cell sources, are not controversial. Moreover,
these cells are likely exempt from incorporated muta-
tions when compared with juvenile or adult donor cells
such as skin fibroblasts or keratinocytes. Unfortunately,
they are only available for a minority of individuals who
have had their samples banked at birth.
Peripheral blood cells (PBCs) can be isolated by rou-
tine venipuncture with minimal risk to the donor and
can be obtained in sufficient numbers to enable repro-
gramming without the need for prolonged expansion in
culture. More importantly, PBCs provide convenient ac-
cess to numerous patient samples stored in blood banks.
Frozen blood samples, when reprogrammed to iPSCs,
are of major interest because they would allow for retro-
spective molecular analysis of rare diseases. However,
some disadvantages associated with the blood specimens
restrict their usage for generation of iPSCs. First, theefficiency of this cell source is extremely low (0.0008 to
0.001%). Second, the main parent cells are mature T cells
bearing specific T cell receptor (TCR) re-arrangements
[51,52], which yield iPSCs with germ line IgH and TCR
alleles, that are undesirable for some potential applica-
tions in regenerative medicine. Moreover, in cases where
blood infections are involved (e.g., hepatitis C virus, and
HIV), giving blood is not exempt of concerns. Finally,
reprogramming may be problematic in patients with
blood diseases (e.g., hemophilia and leukemia).
Human urine -derived cells (HUCs) are another favor-
able iPSC candidate [53,54], in particular because harvest-
ing is completely non-invasive. In normal physiology,
approximately 2000 to 7000 cells from an extensive net-
work of tubules in the kidney and downstream parts of
the urinary tract (the ureters, bladder, and urethra) be-
come detached into the urine daily. They can be collected
anywhere without medical assistance and are easily ex-
panded. Their efficiency with retroviral pMX vectors con-
taining the cDNAs of human OSKM is between 0.1 and
4%, while their efficiency with oriP/EBNA EVs carrying a
combination of reprogramming factors encoded by OSK,
SV40LT, and the miRNA cluster MIR302–367 through
electroporation is approximately 0.2%. These are quite
high efficiencies for the integration-free reprogramming
method. Therefore, urine samples may be considered a
preferred source for iPSC derivation. However, other re-
ports indicate that the number of excreted cells range
from 0 to 6500 showing a high degree of individual vari-
ation, and cell proliferation is achieved in only approxi-
mately 1/3 of the samples [55]. This raises the questions
whether HUCs can be universally applied for generating
iPSCs. Moreover, culturing HUCs usually requires long
periods of time (3 ~ 6 days or more to form the HUC
clones, 7 ~ 10 days or more for the clones to spread over
the dish) prior to the introduction of reprogramming fac-
tors into passage 2 ~ 4 HUCs [53]. Furthermore, although
HUCs may produce iPSCs bearing fewer somatic cell mu-
tations and copy number variations than iPSCs from the
skin due to reduced direct exposure to radiation, iPSCs
derived from this source have not yet been fully analyzed
for the spectrum of mutations and other characteristics
of iPSCs.
Cells of some tissue origins are excluded from easily-
accessible cell resources because they are difficult to
reach, with potential risks due to their positions in the
body. These cell types include neural stem cells (NSCs),
melanocytes, meningiocytes, hepatocytes, gastric epithe-
lial cells, and pancreatic β cells.
Efficiency
Parent cells of different tissue origins have different effi-
ciencies. Researchers have tried to generate iPSCs from
derivatives of the three embryonic germ layers and have
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have different efficiencies. Some cell types are difficult to
reprogram even with a virus-mediated method, let alone
a non-integrating method. It is conceivable that epithe-
lial cells are more amenable to reprogramming, perhaps
because unlike fibroblasts, they need not undergo a
mesenchymal-to-epithelial transition to produce iPSCs.
Nevertheless, the high endogenous levels of transgenes
required for iPSC generation in parent cells may also be
associated with transcriptional and epigenetic states that
are favorable to reprogramming. A detailed summary of
the efficiency of various cell origins other than fibro-
blasts is shown in Table 2.
Number of exogenous factors
Parent cells of different tissue origins require a different
number of exogenous factors. Considering that the ectopic
expression of c-Myc causes tumorigenicity in offspring
and that retroviruses themselves can cause insertional mu-
tagenesis, iPSCs generated with a minimal number of fac-
tors were studied to identify cell types that can be more
easily reprogrammed with fewer factors and with higher
efficiency to increase the likelihood of ultimately replacing
the remaining factors with small molecules.
Mouse and human fibroblasts can be reprogrammed
into iPSCs in the absence of the c-Myc retrovirus, al-
though their efficiency is as low as <0.001% [25]. Fur-
thermore, it is believed that c-Myc plays a much smaller
role in the generation of iPS-Hep and iPS-Stm cells than
in iPS-fibroblasts [59]. This is because the omission of c-
Myc decreased the colony numbers to 20 to 40% of those
obtained by the four factors, in contrast to the generation
of iPS-fibroblasts, which caused a 90% decrease in colony
numbers in response to c-Myc omission.
Adult mouse NSCs express higher endogenous levels
of Sox2 and c-Myc than ESCs. Exogenous Oct4 in com-
bination with either Klf4 or c-Myc is found to be suffi-
cient to generate iPSCs from NSCs [63], while Oct4
alone is confirmed to be both necessary and sufficient
[64]. However, although this approach is potentially ap-
plicable for generating hiPSCs, it is limited by the diffi-
culty and potential risks of obtaining NSCs from the
brains of patients.
Melanocytes are, like NSCs, of neuroectodermal origin
and hence might require fewer factors for their conversion
into iPSCs. Interestingly, with dox-inducible lentiviral vec-
tors expressing OSKM, the efficiency of reprogramming
melanocytes is more than 3-fold higher than that of fibro-
blasts (0.19% versus 0.056%); this efficiency decreases to
0.03% with all three factors (with OKM) and to 0.02% in
the absence of ectopic c-Myc, which is approximately
10-fold lower than the efficiency of melanocyte repro-
gramming in the presence of c-Myc and fibroblast re-
programming [63].Epigenetic memory
iPSCs of different tissue origins are discovered to have
different epigenetic memories when analyzed for DNA
methylation. iPSCs derived from non-hematopoietic cells
(neural progenitors and fibroblasts) are found to retain
residual methylation at various loci where demethylation
is required for a hematopoietic fate, as a result, they
manifest a reduced blood-forming potential in vitro
[68,69]. Epigenetic memory has a dual nature. For some
applications, the epigenetic memory of the donor cell may
be advantageous when the directed differentiation to spe-
cific tissue fates is challenging; for others, epigenetic
memory can restrict the use of the resultant iPSCs in re-
generative medicine. For example, iPSCs generated from
T cells from human PBMCs still contain TCR, restricting
their broad application in regenerative medicine [52].
Differentiation potential
The tissue origin of iPSCs affects their differentiation
potential [70]. For example, the teratoma-forming pro-
pensity is different of secondary neurospheres generated
from 36 mouse iPSC lines derived in 11 different ways.
These iPSC lines can be characterized by (i) their origin
(e.g., MEF, TTF, hepatocyte, or gastric epithelial cell); (ii)
the presence or absence of c-Myc retroviral transduc-
tion; (iii) the presence or absence of drug selection for
Nanog or Fbxo15 expression. Retrovirus-derived iPSCs
from adult TTFs and hepatocytes could contribute to
chimeric mice; however, when the iPSCs are induced
in vitro to differentiate into neural cells, they frequently
form teratomas following cell transplantation. In con-
trast, iPSCs prepared from MEFs show low teratoma for-
mation, similar to ESCs.
Furthermore, the differentiation propensity and methy-
lation profile of iPSCs can be reset. When blood-deficient
neural progenitor-derived iPSCs are differentiated into
blood cells, which are then reprogrammed into iPSCs,
their blood-forming potential is markedly increased [69].
Susceptibility to tumorigenesis
The use of viruses encoding the reprogramming factors
contributes undeniably to the tumorigenesis of iPSCs
because even low vector expression may alter the differ-
entiation potential of iPSCs or induce malignant trans-
formation, and viral transgenes could also be integrated
into the somatic genome. For example, mouse iPSCs
generated from retrovirus-mediated reprogramming of
fibroblasts give rise to adult chimeras and show compe-
tence for germline transmission; however, the chimeras
and progeny mice derived from iPSCs frequently develop
tumors [16]. However, tissue sources of iPSCs seem to
play a role in their susceptibility to tumorigenesis
through the viral-integrating method. Just as in mice
and via the same methods, hepatocytes and gastric
Table 2 The efficiency of cells of various non-fibroblast origins for generating iPSCs
Germ layer Cells Methods Efficiency (%) Reference
Mesoderm Human fibroblast-like synoviocytes OSKM/retrovirus 0.002 [2]
hASCs OSKM/lentivirus 0.4 [42]
hASCs OSKM + VPA + Vc/retrovirus 7.06 [32]
hASCs OSNL cassette/minicircle DNA ~0.005 [39]
Immature B lymphocytes of mouse iPS chimeras Carry dox-inducible OSKM retroviruses already - [56]
Mature B lymphocytes of mouse in the
iPS chimeras
Carry dox-inducible OSKM retroviruses
already + C/EBPalpha) or Pax 5 knockdown
1/30
Terminally differentiated T lymphocytes
of p53-null mouse
OSKM/retrovirus 0.00015 [30]
G-CSF mobilized human CD34+ PBCs OSKM/retrovirus 0.01 ~ 0.02 [47]
0.002
Human CB-derived ECs OSNL/lentivirus 0.01 ~ 0.03 [50]
Mouse BW progenitor cells OSKM/retrovirus 0.00002 ~ 0.00006 [49]
Human CD133+ CB cells OSKM,OSK,OS/retrovirus 0.002 ~ 0.007(OSK) [57]
Human PBMCs (T cell and myeloid cell) OSKM polycistronic expression
cassette/dox-inducible lentivirus
0.001 ~ 0.0002 [51]
Human PB CD34+ cells OSKM/two rounds of lentiviral infection 0.002 [52]
Human T cell in PBMCs 0.0008 ~ 0.001
Human and murine CMCs and periosteal
membrane
pMX-OSKM cDNA/retrovirus + Vc + VPA higher than UMCs [32]
Human UMCs pMX-OSKM cDNA/retrovirus + Vc + VPA 0.4 [33]
Human AMCs 0.1
Oral mucosa fibroblasts OSKM/retrovirus 0.022 [58]
Endoderm Mouse liver and stomach cells OSKM/retrovirus _ [59]
Mouse pancreatic β cells OSKM/inducible lentivirus 0.1 ~ 0.2 [60]
HUCs Retroviral pMX vectors containing the cDNAs of
mouse OSKM
0.1 ~ 4 [53]
HUCs OSK + SV40LT + MIR302–367/EV electroporation 0.2 [54]
Human nasal epithelial cells OSKM/SeV 0.08 ~ 0.10 [61]
Human dental pulp cells OSK/retrovirus 0.01 ~ 0.10 [62]
Ectoderm Mouse NSCs OSKM/retrovirus 3.6 [63]
Oct4 with either Klf4 or c-Myc/retrovirus 0.11
Oct4/retrovirus 0.014 [64]
Mouse meningiocytes pMX of OSKM-cDNAs/retroviral 0.8 [65]
Human keratinocytes OSKM/retrovirus 1 [45]
OSKM/a single polycistronic retrovirus - [29]
Mouse and human melanocytes OKM or OKS/dox-inducible lentivirus 0.19 [66]
Human DP cells from hair follicles OSKM/pMX-based retrovirus 1.38 [46]
OK/pMX-based retrovirus 0.024
Chimeras Cells of mouse iPS-cell chimeras OSKM/dox-inducible polycistronic lentiviruses _ [67]
dox: doxycycline; CMCs: chorionic mesenchymal cells; UMCs: mesenchymal-like cells from the umbilical cord matrix; AMCs: the amniotic membrane mesenchyme.
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programmed but also require fewer retroviral integra-
tions than fibroblasts. No increased tumorigenicity was
observed in chimera mice derived from iPS-Hep and
iPS-Stm cells evaluated up to 30 weeks.Somatic coding mutations of iPSCs have been con-
firmed to be different even with the same cell origin of
different fibroblast lines when different integrating and
non-integrating methods are used [43]. However, no
data exists regarding somatic coding mutations of iPSCs
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free delivery methods are used.
Improvements in the approaches for iPSC generation
The currently available methods for iPSC induction can
be divided into four categories based on their vector
types: viruses, DNA and RNA (plasmid, episomal plas-
mid, and transposon), cell penetrating peptides, and che-
micals. Although retroviral and lentiviral vectors have a
high reprogramming efficiency, the use of viruses encod-
ing reprogramming factors represents a major limitation
of the technology because even low vector expression
may alter the differentiation potential of iPSCs or induce
malignant transformation, while viral transgenes can also
be integrated into the somatic genome. Several groups
have made considerable progress to overcome such
technical problems. iPSCs can be generated without the
oncogenes c-Myc and Klf4 [26]. Furthermore, genome-
integrating but excisable systems have worked to remove
the integrated transgenes [71,72]. Transient expression
of reprogramming factors with adenoviral [27], SeV [31],
and non-viral delivery integration-free methods such as
plasmid [34], EV [35], proteins [36,37], and chemicals
[41] have been successfully employed, albeit at a very
low efficiency (with the exception of SeV). Nevertheless,
further study should focus on whether there is any dif-
ference in the characteristics of iPSCs established by dif-
ferent methods prior to their eventual use in medical
applications.
Viral induction of iPSCs
According to the original method of iPS generation, cells
were reprogrammed into an ESC-like state by viral trans-
duction with defined combinations of factors. Thomson
et al. [9] found that each iPS clone contained three to six
retroviral integrations for each factor. Thus, each clone
had more than 20 retroviral integration sites in total,
which may increase the risk of tumorigenesis. In contrast,
c-Myc is known as a proto-oncogene, and its reactivation
may give rise to transgene-derived tumor formation [16].
Furthermore, although reprogramming has been achieved
in the absence of c-Myc [25], the remaining integrated re-
programming factors could also cause tumor formation
[73]. To apply this technology to cell transplantation ther-
apy, it is crucial to generate iPSCs with fewer viruses and
transgenes.
Induction with varying numbers of transgenes
Transgene numbers can be decreased by changing the
parent cell type. Considering that the ectopic expression
of transgenes can cause tumorigenicity in offspring, the
generation of iPSCs with a minimal number of factors
has been extensively studied. Indeed, studies have shown
that it is possible to generate iPSCs in the absence of c-Myc with retroviruses from mouse and human fibro-
blasts [25] and from mouse hepatocyte and stomach
cells [59], to generate pluripotent stem cells with only
oct4 from adult mouse NSCs [64], and to generate pluri-
potency with dox-inducible lentiviral vectors expressing
OSK or OKM from melanocytes [66].
Some small molecules could also replace certain ex-
ogenous factors. When reprogramming primary human
fibroblasts to a pluripotent state, VPA enables repro-
gramming with OS alone with an efficiency similar to
that of OSK, suggesting that VPA treatment effectively
obviates the need for Klf4 [23]. Kenpaullone could activate
Nanog expression in mouse fibroblasts and substitute for
Klf4, although the underlying mechanism remains unclear
[74]. A specific glycogen synthase kinase 3 (GSK-3) inhibi-
tor, CHIR99021, can induce reprogramming of MEFs
transduced with only OK. When combined with Parnate
(also known as tranylcypromine), an inhibitor of lysine-
specific demethylase 1, namely CHIR99021, human pri-
mary keratinocytes can also be reprogrammed through
transduction with OK [75]. The transient expression of
OCT4 alone with the use of VPA and BIX01294, a histone
methyltransferase G9a inhibitor, is sufficient to allow for
reprogramming of NSCs [76]. In addition, the pan-Src
family kinase (SFK) inhibitors Dasatinib and PP1 are able
to replace Sox2 for the generation of iPSCs from MEF [77].
Hou et al. identified a specific chemical combination of
four small molecules: VPA, tranylcypromine, CHIR99021,
and 616452 (VC6T). These four molecules are sufficient
to permit the reprogramming of mouse embryonic and
adult fibroblasts in the presence of a single transcription
factor, Oct4, which can replace SKM. Two years later, they
generated iPSCs using only seven chemicals [41].
Drug-inducible transgenic systems
Induced pluripotency is complicated by the need for in-
fection with high-titer retroviral vectors, which produce
genetically heterogeneous cell populations. Wernig et al.
generated iPSC chimeras and produced genetically
homogeneous ‘secondary’ somatic cells that carry repro-
gramming factors defined as dox-inducible transgenes
[67]. A drug-inducible transgenic system could directly
reprogram multiple ‘secondary’ somatic cell types with-
out the need for a virus. These cells could be repro-
grammed upon dox exposure without the need for viral
infection with 25- to 50-fold greater efficiencies than
those observed using direct infection and drug selection
for pluripotency marker reactivation.
Technically speaking, this method should not be catego-
rized as a non-virus induction method because primary fi-
broblasts are infected with dox-inducible lentiviruses
encoding OSKM and chimeric mice are generated after
blastocyst injection of iPSCs. Nevertheless, this drug-
inducible transgenic system is quite useful in transfecting
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transfected by transgenes.Single polycistronic vector
The nucleofection of a single polycistronic vector to
generate iPSCs can reduce transgene insertion into the
genome. A major impediment to the use of iPSCs for
therapeutic purposes has been the viral-based delivery of
reprogramming factors; multiple proviral integrations
pose a greater danger of insertional mutagenesis. On the
other hand, the cellular and genetic heterogeneity of fi-
broblasts randomly infected with a single transgene
coded by a separate virus complicates the exploration of
important molecular events occurring during repro-
gramming and limits the scalability required for high-
throughput analyses. Carey et al. reported an approach
to deliver up to four reprogramming factors in a single
virus using 2A “self-cleaving” peptides. These peptides
support efficient polycistronic expression from a single
promoter with a single proviral copy in both embryonic
and adult somatic mouse cells as well as in human kera-
tinocytes [29]. These iPSC lines show no evidence of
transgene insertion into their genomes. Most of all, the
single polycistronic vector could generate genetically
identical cell populations amenable to reprogramming
without any further genetic interference. Several similar
methods [78–80] have been reported in the same year,
and these methods are widely used to this day.An integrating but excisable system
To derive hiPSCs that were free of proviruses, Soldner
et al. used dox-inducible lentiviral vectors that could be
excised after integration with Cre-recombinase [71].
Vectors transducing either OSKM or OSK are used to
generate hiPSCs after being transiently cotransfected
with plasmids for Cre-recombinase and EGFP and sub-
sequently EGFP-positive and Cre-expressing cells are
sorted. The excision of all reprogramming factors is con-
firmed by Southern blot analysis with a different restric-
tion digestion. Furthermore, polymerase chain reaction
(PCR) of the genomic DNA with primers specific for
Cre-recombinase confirms that none of the clones has
stably integrated the electroporated plasmids. However,
it should be noted that a number of technical hurdles
complicate the use of Cre-mediated DNA excision from
stem cells, potentially limiting the application of these
methods to easily generate iPSCs free of floxed trans-
genes. First, the delivery of Cre to ESCs or iPSCs is
known to be inefficient. Second, screening methods to
detect successful Cre-recombination may be cumber-
some. Finally, the clumping of cells after the delivery of
Cre may result in mosaic colonies containing some cells
that have failed to undergo Cre-recombination.Sommer et al. improved the method of Soldner et al.
[72]. A novel version of their single polycistronic vector
containing a reporter fluorochrome allows for the direct
visualization of vector excision in living iPSCs in real
time. Cre-recombination efficiency and the excision of
reprogramming transgenes from the resulting iPSCs
could be readily visualized and monitored in individual
living cells and colonies in culture. In addition, through
the excision of only a single vector copy, their approach
minimizes the risk of chromosomal translocations,
which is a significant advance over prior methods. Fur-
thermore, a direct comparison of iPSC clones before and
after excision reveals that the removal of the reprogram-
ming vector markedly improves the developmental po-
tential and differentiation capacity of the iPSCs. It
should be emphasized that their approach leaves ap-
proximately 200 base pairs (bp) of exogenous DNA, pri-
marily viral long terminal repeat (LTR), behind in the
iPSC genome. Although the viral LTR is inactivated in
their studies and possesses no intrinsic promoter/enhan-
cer activity, there is still a theoretical risk that insertional
mutagenesis may arise from this genomically integrated
exogenous DNA.
Papapetrou et al. further improved the above methods
[81] and developed a strategy that includes additional
steps for the mapping of the integration sites in the gen-
ome. Their method also allows for the selection of
clones with few or a single appropriate site for the inte-
gration of the residual LTR.
Adenoviral vector
Adenoviral vectors allow for transient, high-level expres-
sion of exogenous genes without the integration of such
genes into the host genome. Stadtfeld et al. generated
mouse iPSCs (adeno-iPSCs) from fibroblasts and liver
cells [27] at extremely low efficiency of 0.0001% to
0.001%, which is significantly lower than that obtained
with integrating viruses (~0.01 to 0.1%). This is most
likely because many cells do not maintain viral expres-
sion long enough to trigger entry into a state sustained
by endogenous pluripotency factors.
PCR analysis of genomic DNA isolated from adeno-
iPSC clones excludes the possibility of permanent viral
integration. Southern blot analysis using the cDNAs of
the four viral vectors carrying OSKM as probes con-
firmed the PCR results and yielded no evidence for the
continuous presence of adenoviral sequences in the
adeno-iPSCs. Although highly unlikely, they cannot rule
out the possibility that small pieces of adenoviral DNA
have inserted into the genome of adeno-iPSCs but were
not observed given the detection limits of Southern blot
analysis.
A difference in these adeno-iPSCs is that DNA content
analysis showed that 3 out of 13 (or approximately 23%)
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in iPS cells produced with retroviral or lentiviral vectors.
SeV vector
SeV, a RNA virus carrying no risk of altering the host
genome, is shown to be an efficient solution for generat-
ing safe iPSCs in the work of Fusaki et al. [31]. SeV-
derived transgenes are decreased during cell division;
moreover, viruses could be easily removed by antibody-
mediated negative selection utilizing the cell surface
marker HN that is expressed on SeV-infected cells. SeV
is shown to be an ideal vector for generating hiPSC.
First, as emphasized repeatedly, the SeV vector allows
the expression of transgenes without the risk of modify-
ing the host genome. Second, the efficiency of iPSC gen-
eration by gene transduction with SeV vectors is
significantly higher (~1%) compared with other methods,
especially without any transfection reagents or chemi-
cals. Finally, it is easy to select iPSCs that deplete the
viral genome from the cytoplasm.
Although the use of SeV requires stringent steps to
purge the reprogrammed cells of replicating virus and the
sensitivity of the viral RNA replicase to transgene se-
quence content may limit the generality of this repro-
gramming vehicle, this method is still used widely and can
be used to efficiently deliver up to four exogenous genes
into various mammalian cells, including primary tissue
cells and human hematopoietic stem cells [82–86].
Non-viral induction of iPSCs
The development of novel approaches for generating
integration-free iPSCs has eliminated concerns about in-
tegrating virus-associated genotoxicity in clinical appli-
cations. Among the virus-free method, PB transposons
require a second step to remove the transgenes once re-
programming has been achieved. Other one-step non-
virus approaches make use of plasmids [34], minicircle
DNAs [39], human artificial chromosome vectors (HACs)
[40], protein transduction [36,37], and chemicals [41], but
are very inefficient in generating integration-free iPSCs. In
contrast, the use of modified mRNA [38] and oriP/
EBNA1-based EV [35] represent relatively efficient ap-
proaches that have been readily reproduced in different la-
boratories. The current most cost-effective approach is EV
because it does not require the packaging of viral vectors
and only needs simple infection instead of daily or mul-
tiple additions of factors for successful reprogramming.
However, small molecule strategy is much more promis-
ing because of its many advantages.
PB transposons
DNA transposons are genetic elements that can relocate
between genomic sites via a “cut and paste” mechanism.
PB is originally isolated from Trichoplusia ni andsubsequently found to be a host-factor-independent
method for efficient transposition in many different spe-
cies. The PB transposon/transposase system requires only
the inverted terminal repeats flanking a transgene and
transient expression of the transposase to catalyze inser-
tion or excision events. One important feature of the PB
transposon is that it nearly always excises itself precisely,
leaving no footprint behind [87].
Woltjen et al. demonstrated the successful and effi-
cient reprogramming of murine and human embryonic
fibroblasts using the dox-inducible OSKM transcription
factor delivered by PB transposition [88]. By taking ad-
vantage of the natural propensity of the PB system for
seamless excision, the individual insertions can be re-
moved without a trace from the established iPSC lines,
providing an invaluable tool for discovery. The success-
ful transposon-based reprogramming of fibroblasts to
iPSCs represents a significant advance in the methods of
transgene delivery. First, PB transposition permits technical
simplification and improved accessibility of reprogramming
methodology, making use of effortless plasmid DNA prep-
aration and commercial transfection products for delivery.
This eliminates the need for specialized biohazard contain-
ment facilities and the production of high-titer, limited-
lifetime viral stocks. Second, the range of somatic cell types
that could be used for reprogramming is not limited by a
decreased susceptibility to viral infection. Third, PB-
mediated delivery will allow the option of xeno-free hiPSC
production, contrary to current viral production protocols
that use xenobiotic conditions. Finally, accurate transgene
removal through transposase expression has been demon-
strated in various cell lines. However, it is disadvantaged by
labor intensive removal of multiple transposons.
Meanwhile, in the same journal, Kaji et al. reported
that the non-viral transfection of a single multiprotein
expression vector, the 2A-peptide-linked reprogramming
cassette MKOS-ires-mOrange, could reprogram both
mouse and human fibroblasts [89]. Moreover, the trans-
gene could be removed once reprogramming had been
achieved, when the single vector reprogramming system
is combined with the PB transposon.
Although the PB transposon is thought to nearly always
excise itself precisely, leaving behind no footprint, it is still
found that significantly more CNVs are present in early-
passage than in intermediate passage hiPSCs, as has been
established by retroviral delivery methods [44]. Fortu-
nately, most CNVs are a disadvantage to the affected cells.
Remarkably, the expansion of hiPSCs in culture rapidly se-
lects against mutated cells, driving the lines toward a gen-
etic state resembling that of human ES cells.
Plasmid vector
Okita et al. placed cDNAs encoding OSK into a single ex-
pression vector and c-Myc into another plasmid (pCX-
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colony formation when the factors were in the order of
OKS [34]. Interestingly, when they transfect pCX-OKS-2A
on days 1 and 3, and pCX-cMyc on days 2 and 4, PCR
analyses detected plasmid incorporation into the host gen-
ome. However, after the transfection protocol was modi-
fied to transfect pCX-OKS-2A and pCX-cMyc together on
days 1, 3, 5, and 7, southern blot analyses did not detect
any integration of the transgenes into the clones, while
two of 11 GFP-positive clones were observed with amplifi-
cation of the plasmid DNA. Nevertheless, the efficiency of
the establishment of plasmid-iPSCs is very low; in 2010,
the same group again reported that the efficiency is
0.0001 ~ 0.0003%, and this method is only applied to
MEFs [90].
OriP/EBNA1 EV
Yu et al. reported that hiPSCs completely free of vector
and transgene sequences could be derived from fibro-
blasts by a single transfection with oriP/EBNA1-based
EV [35]. Derived from the Epstein-Barr virus, oriP/
EBNA1 vectors are well suited for introducing repro-
gramming factors into human somatic cells. These plas-
mids can be transfected without the need for viral
packaging and can be subsequently removed from cells
by culturing in the absence of drug selection. One prob-
lem is that the stable transfection efficiency of the oriP/
EBNA1-based vector is almost two orders of magnitude
less than that of the lentiviral vector OSNL in human
newborn fibroblasts (HNFs). To overcome this problem,
they used internal ribosome entry site 2 (IRES2)-medi-
ated expression of OSNL with oriP/EBNA1-based vec-
tors, and the reprogramming efficiency is improved by
approximately 10-fold (~0.1%). The addition of c-Myc
and Klf4 further improves the reprogramming efficiency
to over 1%. When they cloned all six reprogramming
factors (OSNLKM) into an oriP/EBNA1 vector using
IRES2 for coexpression, they initially failed to yield
hiPSC colonies; possibly due to the toxic effects of high
level c-Myc expression. They next included the SV40
large T gene (SV40LT) and produced iPSCs with a low
efficiency (0.0003 ~ 0.0006).
With EV, exogenous DNA is not integrated into the
hiPSC genome. Due to the gradual loss of cellular EV in
the absence of drug selection, vector and transgene-free
hiPSCs can be isolated through subcloning without fur-
ther genetic manipulation. EV is now regarded as one of
the most cost-effective and successful tools for repro-
gramming of cells of different tissue origins from adult
donors [91–99].
Modified mRNAs
Warren et al. described a simple, non-integrating strat-
egy for reprogramming cells based on the administrationof a synthetic mRNA that is modified to overcome in-
nate anti-viral responses [38,100,101]. They synthesized
mRNAs incorporating modified ribonucleoside bases,
encoding KSOM, and including a modified-RNA encod-
ing LIN28 to form a five-factor cocktail (KMOSL) with
the ability to reprogram four human fibroblasts. This
system has an efficiency of over 2%, two orders of mag-
nitude higher than those typically reported for virus-
based derivations. Moreover, the resultant iPSC colonies
emerge as early as 17 days, in contrast to virus-mediated
iPSC derivations, which typically take four weeks. The
efficiency of HNFs transfected with either KMOS-
modified RNAs or transfected with the KMOS retrovi-
ruses is 1.4% and 0.04%, respectively.
Minicircle DNA
Minicircle DNA is a novel compact vector free of bac-
terial DNA and capable of sustaining high-level expres-
sion within cells. Jia et al. [39] constructed a plasmid
(P2PhiC31-LGNSO) containing a single cassette of OSNL
plus a GFP reporter gene, each separated by self-cleaving
peptide 2A sequences. This system yields an overall repro-
gramming efficiency of ~0.005% in hASCs with minicircle
DNA [102]. This efficiency is higher than that of previous
plasmid-based transfection reprogramming methods, al-
though this may be in part due to differences in donor cell
types (HNFs vs. hASCs) and the number of reprogram-
ming factors used. They then transfected HNFs with a
minicircle vector and attained 10-fold less efficiency.
Although its efficiency is very low, minicircle DNA has
its advantages. Compared with other iPSC derivations
that are free of foreign or chemical elements, minicircle
DNA is a simple method from adult donor sources, re-
quiring only a single vector without the need for subse-
quent drug selection, vector excision, or the inclusion of
oncogenes such as SV40. Finally, minicircle DNA is
already FDA approved, giving this novel method the po-
tential for significant clinical translation.
HACs
HACs possess several characteristics that are required
for gene therapy, including stable episomal maintenance
and the capacity for large gene inserts. HACs can also
carry genomic loci with regulatory elements, thus allow-
ing for the expression of transgenes in a genetic environ-
ment similar to a chromosome [103].
Hiratsuka et al. devised a reprogramming cassette with
four defined reprogramming factors and introduced
multiple copies of the cassette into the cloning site of a
HAC vector [40]. This HAC vector encodes herpes sim-
plex virus thymidine kinase (HSV-TK) such that any
produced iPSCs and/or their HAC-carrying differenti-
ated derivatives can be killed by ganciclovir (GCV). This
provides a safeguard system lest any unexpected events
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tors encode EGFP. Because HACs are lost spontaneously
at a low frequency, HAC-free cells can be isolated from re-
programmed iPS populations by identifying EGFP-negative
cells. The overall efficiency of reprogramming achieved
with the HAC strategy was approximately 0.001%.
Protein delivery systems
Zhou et al. introduced a method using recombinant pro-
teins to induce iPSC formation [36]. To generate recom-
binant proteins that can penetrate the plasma membrane
of somatic cells, they designed and fused a poly-arginine
(i.e., 11R) protein transduction domain to the C-terminus
of OSKM. Four repeated protein transductions of repro-
gramming proteins, with the help of VPA, could repro-
gram the OG2/Oct4-GFP reporter MEF cells into iPSCs
with an efficiency of 0.006%; for comparison, this effi-
ciency is only 0.001% with proteins OSK.
This protein transduction method represents a signifi-
cant advancement in generating iPSCs and has several
major advantages over previous methods. First, it rules
out any risk that the target cell genome will be modified
by transgenes and consequently offers a method to gen-
erate safer iPSCs. Second, the protein transduction
method provides a substantially simpler and faster
approach than the genetic method, which requires time-
consuming sequential selection of potentially integration-
free iPSCs. Finally, given the robustness and wide
availability of large-scale recombinant protein production,
this completely chemically defined reprogramming regi-
men could potentially enable broader and more econom-
ical application of reprogramming methodologies.
Kim et al. reported the generation of stable iPSCs from
human fibroblasts by directly delivering proteins OSKM
fused with a cell-penetrating peptide (CPP) in HEK293
cell extracts [37]. When the HNFs are treated with cell
extracts, efficient intracellular translocation of each re-
combinant protein was observed within eight hours. Re-
peated protein treatment cycles (with 16 hours of
protein treatment followed by six days of incubation in
ES media) could yield hiPSCs starting from the 6th
cycle. Overall, the establishment of these hiPS-like col-
onies took approximately eight weeks, approximately
doubling the time required for viral transduction. At
present, the efficiency of iPSC generation is significantly
lower using this protein-based protocol (approximately
0.001%). In particular, the whole protein extracts used in
the present study limited the concentrations of factors
delivered into the target cells, suggesting that iPSCs may
be more efficiently generated using purified reprogram-
ming proteins.
Compared to the work of Zhou et al., who reported
that mouse iPSCs were not generated when only recom-
binant proteins were used, the system of Kim et al.generated hiPSCs with the direct delivery of reprogram-
ming proteins in the absence of any chemical treatment.
One possible explanation for these differences is that
Kim et al. used reprogramming proteins expressed in
mammalian cells, whereas Zhou et al. used refolded pro-
teins after their expression in E. coli.
In general, protein-based iPSC generation requires ei-
ther chemical treatment (e.g., VPA) or greater than four
rounds of treatment. Furthermore, protein-based methods
necessitate expertise in protein chemistry and handling,
which are skills that many laboratories do not have. For
these reasons, recombinant proteins are challenging to
generate and purify in the quantities required. Lastly, low
iPSC derivation efficiencies have been observed, presum-
ably due to weak or non-constant expression of repro-
gramming factors.
Small-molecule compounds
In their search for chemicals that could replace the
transgenes needed to reprogram iPSCs, Hou et al.
showed that pluripotent stem cells can be generated
from mouse somatic cells at a frequency of up to 0.2%
using a combination of just seven small-molecule com-
pounds [41]. They confirmed for the first time that by
using small molecules, exogenous “master genes” are
dispensable for cell fate reprogramming. Small molecules
have many advantages because they can be cell perme-
able, non-immunogenic, more cost-effective, and more
easily synthesized, preserved, and standardized. More-
over, their effects on inhibiting and activating the func-
tion of specific proteins are often reversible and can be
finely tuned by varying their concentrations. This chem-
ical reprogramming strategy has powerful potential for
use in generating functional desirable cell types for fu-
ture clinical applications. However, current reprogram-
ming methods that do without transcriptional factors
have relatively low and inconsistent efficiency. The tim-
ing and dosage of specific small molecules need to be
optimized. Moreover, the generation of iPSCs from hu-
man somatic cells using this strategy has not yet been
reported.
Perspectives
Successfully reprogramming somatic cells to a pluripo-
tent state represents a significant advancement in stem
cell research. To determine the range of tissue types
amenable to reprogramming and their particular charac-
teristics, to reduce tumorigenesis risk of transgene inte-
gration, and to increase the efficiency of induction,
many efforts have been put on the selection of ideal
donor cells and optimization of iPSCs approaches. The
huge potential implications of disease-specific or
patient-specific iPSCs have impelled scientists to solve
problems hindering the applications of iPSCs in clinical
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clinical application involves a thorough investigation of
the most favorable tissue origin for iPSCs generation. Al-
though fibroblasts are the first cell type from which
iPSCs are developed and are still being widely used, they
are not the ideal source. The procedure requires biopsy
and is contraindicated in life-threatening skin diseases.
To date, cells from all three embryonic germ layers have
been analyzed by comparing with fibroblasts, and advan-
tages of some tissue origins over fibroblasts were identi-
fied. PBSs and HUCs are the most promising sources forDon
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Moreover, culturing HUCs usually requires long periods
of time (at least two weeks) [53]. Furthermore, iPSCs de-
rived from this source are not fully analyzed so far regard-
ing genomic stability and differentiation potential. Thus,
further efforts are still needed to identify the ideal tissue
for iPS generation that would be effective, safe, and con-
venient. A second major breakthrough is the elimination
of the integration of the viral transgenes into the somatic
genome. Current methods for iPSC induction can be di-
vided into four categories based on their delivery system:
viruses, DNA and RNA (plasmid, episomal plasmid, and
transposon), cell-penetrating peptides, and chemicals. An-
other classification is based on genome-integration: inte-
gration, integration but excisable, and integration-free
methods. Non-viral delivery integration-free methods,
such as plasmid [34], EV [35], proteins [36,37], and chemi-
cals [41], have been successfully employed to produce
integration-free iPSCs, albeit at a lower efficiency than
retroviral and lentiviral methods. The reasons for the low
efficiency of iPSC induction are unclear, but it may be that
the precise balance between transgenes and/or the expres-
sion level of each transgene is important for reprogram-
ming [18]. Generally, EV is now regarded to be one of the
most cost effective, non-viral, integration-free vectors at
present. It should be emphasized that the small molecule
strategy is much more promising because of its outstand-
ing advantages. Small molecule compounds can be cell
permeable, non-immunogenic, and more easily synthe-
sized, preserved, and standardized. Moreover, their ef-
fects on the function of specific proteins are often
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Figure 2 Schematic representation of delivery systems used for iPS in
integration-free approaches and the challenges encountered. Non-vira
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potential immunogenicity against transplanted iPSCs as well as other challemicroenvironment. This strategy could be more cost-
effective if the efficiency of could be improved.
It is far too early to know for sure whether hiPSCs are
safe for use in medical applications. Although hiPSC
lines generated by integration-free methods are not
found to have integrated transgenes by Southern blot
analyses and PCR analyses, small pieces of vectors and
transgenes could be inserted into the genome but not
observed, given the detection limits of ordinary methods.
Thus, because it is important to validate the quality of
iPSCs, extensive genetic screening should become a
standard procedure to ensure the safety of hiPSCs prior
to their clinical use. Another pitfall that was discovered
recently is potential immunogenicity against trans-
planted iPSCs. Immune tolerance had been considered
an advantage of autologous cell transplantation derived
from patient iPSCs. However, it is found that some cer-
tain but not all tissues derived from iPSC-derived cells
can be immunogenic in syngenic hosts by using a tera-
toma transplantation model. The reasons for this
phenomenon are very complicated, and both genetic and
epigenetic defects in iPSCs could contribute either dir-
ectly or indirectly [104]. In vivo immunogenicity testing
should be used as a screening platform to improve the
reprogramming technology [105].
Conclusions and future directions
Generally speaking, researches to develop new methods
for iPS cell generation for clinical applications are an on-
going process. The range of tissue origins seems to have
been extensively investigated, but we still have to find an
ideal one for real practical application; rather, it is bestsystem
Non-virus delivery
ve but excisable Non-integrative
EV Modified RNA
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http://www.jhoonline.org/content/7/1/50to find one that most suit for a given application. For in-
stance, PBSs which possess strong blood-forming poten-
tial are attractive for hematologists whereas DP cells
maybe a better cell source for dermatologists to grow
hairs. More efforts should be put on the improvement of
the culture conditions and technology (see Figure 1). As
for the approaches used to generate iPSCs, although they
have been improved from viral integration to integration-
free, there are still many challenges down the road to
achieve their clinical application in humans (see Figure 2).
It counts on further improvement of current reprogram-
ming technology to minimize the genetic and epigenetic
difference between iPSCs and donors. In addition, a more
comprehensive understanding of the reprogramming
process will be crucial for the development of future ap-
proaches for clinical applications of iPSCs.
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